RNA Silencing in the Management of Dyslipidemias

Henney, Neil C, Banach, Maciej and Penson, Peter E ORCID: 0000-0001-6763-1489 (2021) RNA Silencing in the Management of Dyslipidemias. CURRENT ATHEROSCLEROSIS REPORTS, 23 (11). 69-.

Text
RNA Silencing in the Management of Dyslipidemias.pdf - Published version
Download (992kB) | Preview

Official URL: http://dx.doi.org/10.1007/s11883-021-00968-7

Abstract

<h4>Purpose of review</h4>Remarkable reductions in cardiovascular morbidity and mortality have been achieved in recent decades through the widespread use of 'small-molecule' hypolipidaemic drugs such as statins and ezetimibe. An alternative approach is to perturb the production of proteins through ribonucleic acid (RNA) silencing, leading to long-lasting knock-down of specific biological molecules. This review describes the scientific basis of RNA silencing, and critically evaluates the evidence relating to inclisiran, a small interfering RNA against proprotein convertase subtilisin kexin 9 (PCSK9).<h4>Recent findings</h4>Pooled analysis of three recent ORION trials has demonstrated that twice-yearly administration of inclisiran reduces LDL-C by 50% in a range of patient groups, with only mild adverse effects. Inclisiran provides safe, effective and long-lasting reductions in PCSK9 and LDL-C. The results of the phase-3 ORION-4 outcomes study are eagerly awaited. Further promising RNA silencing technologies have the potential to improve the management of dyslipidaemia.

Item Type:	Article
Uncontrolled Keywords:	Inclisiran, LDL cholesterol, Dyslipidaemia, Atherosclerosis, siRNA
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User:	Symplectic Admin
Date Deposited:	20 Dec 2021 17:26
Last Modified:	18 Jan 2023 21:18
DOI:	10.1007/s11883-021-00968-7
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3145721